Brief Summary

Quince Therapeutics reported a 2024 fiscal year net loss of $56.83 million with zero revenue, resulting in an EPS of -$262.71, which missed the market’s expectation of -$240.50.

Impact of The News

Financial Performance vs. Market Expectations